Home › Compound Library › Alpha-PVP (Flakka)

Alpha-PVP (Flakka)

Stimulantoral · inferred

Extremely dangerous synthetic cathinone (alpha-pyrrolidinopentiophenone) and potent dopamine/norepinephrine transporter inhibitor. VERY DANGEROUS: produces severe psychomotor agitation, excited delirium, psychosis, hyperthermia (>40C), rhabdomyolysis, and acute kidney injury. Numerous fatalities reported. Effects onset in ~10 min (intranasal), peak at 10-40 min, last 2-3 hours. Highly addictive with intense compulsive redosing.

Projected serum levels — 10 mg, as needed (shown daily)

Alpha-PVP (Flakka)
Alpha-PVP (Flakka) modeled serum levels, 10 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 10 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 3.0 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Stimulant
Route modeled
Oral
Model confidence
inferred
Half-life
1.7 h
Common dose
10 mg
Reference dose range
5–20 mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Alpha-PVP (Flakka) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Alpha-PVP (Flakka) AUC by ~0.47x

  • danger
    Efavirenz (Sustiva) + Alpha-PVP (Flakka) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Alpha-PVP (Flakka) AUC by ~0.33x

  • danger
    MDA (3,4-Methylenedioxyamphetamine) + Alpha-PVP (Flakka) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change Alpha-PVP (Flakka) AUC by ~2.06x

  • danger
    MDMA (Ecstasy) + Alpha-PVP (Flakka) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change Alpha-PVP (Flakka) AUC by ~2.06x

  • danger
    Paroxetine (Paxil) + Alpha-PVP (Flakka) CYP inhibition

    Paroxetine (Paxil) mechanism_based of CYP2D6 predicted to change Alpha-PVP (Flakka) AUC by ~2.06x

  • danger
    Rifampin + Alpha-PVP (Flakka) CYP induction

    Rifampin inducer of CYP3A4 predicted to change Alpha-PVP (Flakka) AUC by ~0.33x

Serum checks 95 modeled interaction pairings for alpha-pvp (flakka) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. The synthetic cathinone alpha-pyrrolidinovalerophenone (alpha-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects Nobrega L, Dinis-Oliveira RJ · Drug Metabolism Reviews, 2018 DOI

    Review of alpha-PVP toxicokinetics covering limited human PK data, DAT/NET inhibition mechanism, and forensic case analyses of fatal and non-fatal intoxications.

  2. DARK Classics in Chemical Neuroscience: alpha-Pyrrolidinovalerophenone ("Flakka") Kolesnikova TO et al. · ACS Chemical Neuroscience, 2019 DOI

    Comprehensive review of alpha-PVP history, synthesis, potent DAT/NET inhibition, metabolism, extreme abuse potential, and societal impact including numerous fatalities and excited delirium cases.

2 published studies referenced in the app, each with a plain-language summary.